Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
technetium-99m diphosphonate
- Development stage
- Unknown
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Small Molecules
- Administration
- Intravenous
01
Overview
Technetium-99m diphosphonate is a generic class of diagnostic radiopharmaceuticals used as bone scanning agents in nuclear medicine. It consists of a small-molecule chelate of the radionuclide technetium-99m complexed with a diphosphonate carrier, such as methylene diphosphonate (MDP) or hydroxydiphosphonate (HDP). Following intravenous injection, the agent localizes to bone surfaces by chemisorption onto hydroxyapatite crystals, with uptake depending on local blood flow and osteoblastic activity. It is widely used in gamma scintigraphy and single-photon emission computed tomography (SPECT) to image skeletal conditions, including Paget's disease, fractures, osteomyelitis, bone tumors, and bone metastases, as well as to differentiate cardiac transthyretin amyloidosis (ATTR) from light chain amyloidosis (AL).
- Brand names
- CIS-MDPDraximage MDPDraximage MDP-25MPI MDPOsteoliteTechneScan HDPTechneScan MDP
- Other names
- 99mTc-DP99mTc-diphosphonatetechnetium-99m-diphosphonatetechnetium99m-diphosphonatetechnetium 99m-diphosphonatetechnetium-99m diphosphonatestechnetium99m diphosphonatestechnetium 99m diphosphonates
Beyond the preview
Go deeper on technetium-99m diphosphonate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on technetium-99m diphosphonate.